ProQR Therapeutics N.V.
PRQRNASDAQHealthcare● Active
$1.53
+$0.03(+2.00%)
Market Cap$161202330
P/E Ratio—
52W High$3.1
52W Low$1.33
ProQR Therapeutics N.V. (PRQR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PRQR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.15
Est. -$0.15 · +0.0%
Revenue
$0.00B
Est. $0.01B · -54.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
PRQR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.16 | — | — | — | $0.00B | — |
| — Q2 FY2026 | May 12, 2026 | -$0.15 | -$0.15 | +0.0% | $0.00B | $0.01B | -54.7% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -$0.08 | -$0.09 | -12.5% | $0.01B | $0.01B | -16.4% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.10 | -$0.12 | -20.0% | $0.00B | $0.01B | -44.2% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.08 | -$0.14 | -75.0% | $0.00B | $0.01B | -18.2% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.09 | -$0.11 | -22.2% | $0.00B | $0.00B | +3.1% |
| — Q1 FY2025 | Mar 13, 2025 | -$0.10 | -$0.10 | +0.0% | $0.00B | $0.01B | -18.1% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.12 | -$0.11 | +8.3% | $0.00B | $0.01B | -39.8% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.16
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026
EPS Actual
-$0.15
EPS Est.
-$0.15
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2026
Mar 12, 2026Miss
EPS Actual
-$0.09
EPS Est.
-$0.08
EPS Surpr.
-12.5%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.12
EPS Est.
-$0.10
EPS Surpr.
-20.0%
Revenue
$0.00B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.14
EPS Est.
-$0.08
EPS Surpr.
-75.0%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.11
EPS Est.
-$0.09
EPS Surpr.
-22.2%
Revenue
$0.00B
Q1 FY2025
Mar 13, 2025
EPS Actual
-$0.10
EPS Est.
-$0.10
EPS Surpr.
+0.0%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.11
EPS Est.
-$0.12
EPS Surpr.
+8.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.23 | $-0.21 | $-0.16 | 1 |
| Q3 FY2027 | $-0.19 | $-0.17 | $-0.13 | 1 |
| Q2 FY2027 | $-0.18 | $-0.16 | $-0.12 | 1 |
| Q1 FY2027 | $-0.15 | $-0.14 | $-0.11 | 1 |
| Q4 FY2026 | $-0.15 | $-0.13 | $-0.10 | 1 |
| Q3 FY2026 | $-0.14 | $-0.12 | $-0.08 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +0.0% | $1.61 | $1.60 | -0.62% |
| ▼ Q1 FY2026 | Mar 12, 2026 | -12.5% | $1.81 | $1.72 | -4.97% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -20.0% | $2.38 | $2.21 | -7.14% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -75.0% | $2.06 | $2.05 | -0.49% |
| ▼ Q2 FY2025 | May 8, 2025 | -22.2% | $1.57 | $1.55 | -1.27% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +0.0% | $1.85 | $1.74 | -5.95% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +8.3% | $3.64 | $3.57 | -1.92% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +75.0% | $1.83 | $2.06 | +12.57% |
Q2 FY2026-0.62%
Report Date
May 12, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.61
Price After
$1.60
Q1 FY2026-4.97%
Report Date
Mar 12, 2026
EPS Beat/Miss
-12.5%
Price Before
$1.81
Price After
$1.72
Q4 FY2025-7.14%
Report Date
Nov 6, 2025
EPS Beat/Miss
-20.0%
Price Before
$2.38
Price After
$2.21
Q3 FY2025-0.49%
Report Date
Aug 7, 2025
EPS Beat/Miss
-75.0%
Price Before
$2.06
Price After
$2.05
Q2 FY2025-1.27%
Report Date
May 8, 2025
EPS Beat/Miss
-22.2%
Price Before
$1.57
Price After
$1.55
Q1 FY2025-5.95%
Report Date
Mar 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.85
Price After
$1.74
Q4 FY2024-1.92%
Report Date
Nov 7, 2024
EPS Beat/Miss
+8.3%
Price Before
$3.64
Price After
$3.57
Q3 FY2024+12.57%
Report Date
Aug 8, 2024
EPS Beat/Miss
+75.0%
Price Before
$1.83
Price After
$2.06
Avg Beat Reaction+1.02%
Avg Miss Reaction-3.47%
Beat Rate4 / 8 quarters
Largest Move+12.57% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PRQR ends December
ProQR Therapeutics N.V. (PRQR) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.15 (in line with the analyst consensus of $-0.15). The next PRQR earnings date is expected around September 1, 2026.
Each quarter, investors track PRQR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PRQR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PRQR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PRQR earnings · 4 questionsProQR Therapeutics N.V.'s next earnings report is expected around September 1, 2026. PRQR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PRQR historically reports after market close (AMC).
PRQR earnings datewhen is PRQR earningsPRQR next earnings datewhen does PRQR report earningsPRQR earnings calendar
▸ Source: FMP · ProQR Therapeutics N.V. SEC filings · US GAAP · ProQR Therapeutics N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026